» Articles » PMID: 33055569

Substantial Decline in Heavily Treated Therapy-experienced Persons with HIV with Limited Antiretroviral Treatment Options

Abstract

Objective: Historically, a high burden of resistance to antiretroviral therapy (ART) in heavily treatment-experienced (HTE) persons with HIV (PWH) resulted in limited treatment options (LTOs). We evaluated the prevalence, risk factors, and virologic control of HTE PWH with LTO throughout the modern ART era.

Design: We examined all ART-experienced PWH in care between 2000 and 2017 in the Centers for AIDS Research Network of Integrated Clinical Systems cohort.

Methods: We computed the annual prevalence of HTE PWH with LTO defined as having two or less available classes with two or less active drugs per class based on genotypic data and cumulative antiretroviral resistance. We used multivariable Cox proportional hazards models to examine risk of LTO by 3-year study entry periods adjusting for demographic and clinical characteristics.

Results: Among 27 133 ART-experienced PWH, 916 were classified as having LTO. The prevalence of PWH with LTO was 5.2-7.5% in 2000-2006, decreased to 1.8% in 2007, and remained less than 1% after 2012. Persons entering the study in 2009-2011 had an 80% lower risk of LTO compared with those entering in 2006-2008 (adjusted hazard ratio 0.20; 95% confidence interval: 0.09-0.42). We found a significant increase in undetectable HIV viral loads among PWH ever classified as having LTO from less than 30% in 2001 to more than 80% in 2011, comparable with persons who never had LTO.

Conclusion: Results of this large multicenter study show a dramatic decline in the prevalence of PWH with LTO to less than 1% with the availability of more potent drugs and a marked increase in virologic suppression in the current ART era.

Citing Articles

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

Rai M, Blazkova J, Kardava L, Justement J, Shi V, Manning M Nat Med. 2025; 31(2):427-432.

PMID: 39753965 DOI: 10.1038/s41591-024-03357-0.


Heavily treatment-experienced patients with HIV: are new mechanisms of action enough?.

Brizzi M, Cable T, Patel D, Williams K, Adjei Z, Fichtenbaum C J Int Med Res. 2024; 52(12):3000605241301883.

PMID: 39633602 PMC: 11618923. DOI: 10.1177/03000605241301883.


US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.

Vardanega V, New E, Mezzio D, Eddowes L J Manag Care Spec Pharm. 2024; 30(9):1001-1012.

PMID: 39213144 PMC: 11365559. DOI: 10.18553/jmcp.2024.30.9.1001.


Development of an extended action fostemsavir lipid nanoparticle.

Islam F, Das S, Ashaduzzaman M, Sillman B, Yeapuri P, Nayan M Commun Biol. 2024; 7(1):917.

PMID: 39080401 PMC: 11289258. DOI: 10.1038/s42003-024-06589-5.


Acquired Human Immunodeficiency Virus Type 1 Drug Resistance in Rhode Island, USA, 2004-2021.

Aung S, Novitsky V, Steingrimsson J, Gillani F, Howison M, Nagel K J Infect Dis. 2024; 230(6):1422-1433.

PMID: 39041648 PMC: 11646588. DOI: 10.1093/infdis/jiae344.


References
1.
Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26. PMC: 2854555. DOI: 10.1056/NEJMoa0807252. View

2.
Swenson L, Min J, Woods C, Cai E, Li J, Montaner J . HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014; 28(8):1125-34. PMC: 4278403. DOI: 10.1097/QAD.0000000000000203. View

3.
Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

4.
Lucas G, Gallant J, Moore R . Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004; 18(11):1539-48. DOI: 10.1097/01.aids.0000131339.68666.1a. View

5.
Gill V, Lima V, Zhang W, Wynhoven B, Yip B, Hogg R . Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2009; 50(1):98-105. PMC: 2922860. DOI: 10.1086/648729. View